These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23781914)

  • 1. Pragmatic clinical trials: U.S. payers' views on their value.
    Ratner J; Mullins D; Buesching DP; Cantrell RA
    Am J Manag Care; 2013 May; 19(5):e158-65. PubMed ID: 23781914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical technology assessment: perspectives from payers.
    Leung MY; Halpern MT; West ND
    J Manag Care Pharm; 2012 Apr; 18(3):256-64. PubMed ID: 22468734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
    Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
    Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
    Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can managed care organizations partner with manufacturers for comparative effectiveness research?
    Luce BR; Paramore LC; Parasuraman B; Liljas B; de Lissovoy G
    Am J Manag Care; 2008 Mar; 14(3):149-56. PubMed ID: 18333707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncertainty in assessing value of oncology treatments.
    Mullins CD; Montgomery R; Tunis S
    Oncologist; 2010; 15 Suppl 1():58-64. PubMed ID: 20237219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of private industry in pragmatic comparative effectiveness trials.
    Buesching DP; Luce BR; Berger ML
    J Comp Eff Res; 2012 Mar; 1(2):147-56. PubMed ID: 24237375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations When Designing and Implementing Pragmatic Clinical Trials That Include Older Hispanics.
    Samper-Ternent R; Silveira SL; Stevens A; Volpi E; Naik AD
    Ethn Dis; 2023 Apr; 33(2-3):76-83. PubMed ID: 38845738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
    Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
    J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Readiness assessment for pragmatic trials (RAPT): a model to assess the readiness of an intervention for testing in a pragmatic trial.
    Baier RR; Jutkowitz E; Mitchell SL; McCreedy E; Mor V
    BMC Med Res Methodol; 2019 Jul; 19(1):156. PubMed ID: 31319789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
    Bero L; Oostvogel F; Bacchetti P; Lee K
    PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
    Rosenblatt M
    J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ethical justification for inclusion of neonates in pragmatic randomized clinical trials for emergency newborn care.
    Kaye DK
    BMC Pediatr; 2019 Jul; 19(1):218. PubMed ID: 31266486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the relevance of randomised trials to primary care: a qualitative study investigating views towards pragmatic trials and the PRECIS-2 tool.
    Forbes G; Loudon K; Clinch M; Taylor SJC; Treweek S; Eldridge S
    Trials; 2019 Dec; 20(1):711. PubMed ID: 31829266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for CER.
    Lowry SJ; Loggers ET; Bowles EJ; Wagner EH
    Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP77-83. PubMed ID: 22693985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans.
    Mazor KM; Sabin JE; Boudreau D; Goodman MJ; Gurwitz JH; Herrinton LJ; Raebel MA; Roblin D; Smith DH; Meterko V; Platt R
    Med Care; 2007 Oct; 45(10 Supl 2):S29-37. PubMed ID: 17909379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.